Pfizer hopes Covid-19 sales will increase in the long run
Citing existing stockpiles around the world, Pfizer does not think it can increase sales of its two Covid-19 products in 2023 – but this development will reverse in the future.
by ulrich quistgaard, translated by daniel pedersen
Pfizer’s 2023 guidance, which was released alongside its annual report on Tuesday, disappointed analysts with respect to the company’s Covid-19 sales expectations for the Paxlovid treatment and the Corminaty vaccine.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
